Tuberculosis
Conditions
Brief summary
There is an urgent need for novel therapies to shorten TB treatment and improve long-term lung function outcomes. Host-directed therapies (HDT) have received significant attention recently given the ability of M. tuberculosis to subvert host immune responses and cause destructive lung pathology. Statins are among the most promising HDT agents for TB. In addition to having a highly favorable safety profile, statins have been shown to have anti-TB activity in macrophages, to synergize with anti-TB drugs, and to shorten the duration of TB treatment in the standard mouse model. The StAT-TB trial will comprise two different stages. In the 14-day Stage 1 study, investigators will test the safety and tolerability, as well as Pharmacokinetics (PK), of two different doses of pravastatin co-administered with standard anti-TB treatment. In Stage 2, investigators will test the ability of pravastatin adjunctive therapy (dose to be determined in Stage 1) to shorten the mean time to sputum culture conversion (primary endpoint) and improve lung function outcomes (secondary endpoints) relative to the standard regimen. In addition, investigators will continue to investigate the anti-TB mechanism of action of pravastatin in order to further improve HDT options for TB in the future.
Interventions
DRUGPravastatin
Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated. A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
Sponsors
Johns Hopkins University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 18 years of age or older * Clinical signs and symptoms of pulmonary tuberculosis * Abnormal chest radiograph consistent with pulmonary tuberculosis * At least one sputum positive for M. tuberculosis by Xpert Mycobacterium tuberculosis (MTB)/resistance to rifampicin (RIF) with a cycle threshold (Ct) \<28. * Documentation of HIV status * Weight ≥45 kg * Karnofsky score of at least 60 * Ability to provide informed consent * Ability to adhere to study follow-up visits * Ability to adhere to contraceptive requirements and willing to use two forms of contraception. * Five days or fewer of anti-tuberculosis treatment within the previous 3 months
Exclusion criteria
* A history of severe adverse reactions to any statin or any other study agent or contraindications to use of statins. * Current use of statins or other lipid-lower agents; * Clinical indication for statin therapy based on cardiovascular risk (Familial hypercholesterolemia, Previous history of myocardial infarction or stroke) * For HIV-positive individuals, a cluster of differentiation 4 (CD4+) T-cell count \<100/mm3 * Use of antiretroviral drugs * Hemoglobin concentration less than 7 g/dL; * Baseline creatinine kinase elevation more than three times the upper limit of normal * Abnormal baseline laboratory values (Baseline alanine aminotransferase (ALT) concentration more than three times the upper limit of normal, Serum creatinine concentration more than twice the upper limit of normal, Serum total bilirubin level greater than twice the upper limit of normal, Platelet count \< 100,000/mm3, White Blood Cell (WBC) \< 2500 (mcL)) * Pregnant or breastfeeding; * Silico-tuberculosis. * Currently receiving TB treatment * Concomitant disorders or conditions for which isoniazid, rifampin, pyrazinamide, or ethambutol is contraindicated. These include sever hepatic damage, acute liver disease of any cause, acute uncontrolled gouty arthritis and peripheral neuropathy. * Any medical or psychological condition which, in the view of the study investigator, makes study participation inadvisable. * Infection with an isolate known to be resistant to a first -line TB drug; for example rifampin. * More than five days of anti-tuberculosis treatment within the previous 3 months * Planned or current use of cyclosporine, tacrolimus, erythromycin or colchicine * Central nervous system (CNS) TB * Extra-pulmonary TB only, not in combination with pulmonary TB * History of TB
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of Escalating Doses of Pravastatin as Assessed by Number of Adverse Events | Up to 30 days | Safety of escalating doses of pravastatin (40 mg - 160 mg) when co-administered with rifampin, as evidenced by number of Grade 3 or higher adverse events. |
Countries
South Africa
Participant flow
Recruitment details
Study participants were recruited from clinics in Soweto, South Africa by the study team at the PHRU, Chris Hani Baragwanath Academic Hospital, Soweto, South Africa. Participants were recruited based on having a sputum specimen that is positive for TB by GeneXpert MTB/RIF.
Participants by arm
| Arm | Count |
|---|---|
| Pravastatin 40 mg Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight \<50 kg) or 600 mg (weight \>50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 80 mg is not tolerated as specified in protocol.
Pravastatin: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated. | 10 |
| Pravastatin 80 mg Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight \<50 kg) or 600 mg (weight \>50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
Pravastatin: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated. | 6 |
| Pravastatin 120 mg Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight \<50 kg) or 600 mg (weight \>50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
Pravastatin: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated. | 0 |
| Pravastatin 160 mg Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight \<50 kg) or 600 mg (weight \>50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days
Pravastatin: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated. | 0 |
| Total | 16 |
Baseline characteristics
| Characteristic | Pravastatin 80 mg | Pravastatin 40 mg | Total |
|---|---|---|---|
| Age, Continuous | 26.83 years STANDARD_DEVIATION 7.03 | 26.70 years STANDARD_DEVIATION 5.35 | 26.75 years STANDARD_DEVIATION 5.8 |
| HIV Status Negative | 6 Participants | 10 Participants | 16 Participants |
| HIV Status Positive | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized African/Black | 6 Participants | 10 Participants | 16 Participants |
| Race/Ethnicity, Customized Coloured | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Indian/Asian | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment South Africa | 6 Participants | 10 Participants | 16 Participants |
| Sex: Female, Male Female | 2 Participants | 3 Participants | 5 Participants |
| Sex: Female, Male Male | 4 Participants | 7 Participants | 11 Participants |
| Weight at Baseline (kg) 45-49kg | 0 Participants | 1 Participants | 1 Participants |
| Weight at Baseline (kg) 50-59kg | 4 Participants | 7 Participants | 11 Participants |
| Weight at Baseline (kg) 60-69kg | 2 Participants | 2 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 0 / 6 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 5 / 10 | 3 / 6 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 4 / 10 | 1 / 6 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Safety of Escalating Doses of Pravastatin as Assessed by Number of Adverse Events
Safety of escalating doses of pravastatin (40 mg - 160 mg) when co-administered with rifampin, as evidenced by number of Grade 3 or higher adverse events.
Time frame: Up to 30 days
Population: Participants were not enrolled in Arms 3 and 4 due to early termination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pravastatin 40 mg | Safety of Escalating Doses of Pravastatin as Assessed by Number of Adverse Events | 8 AEs Grade 3 or Higher |
| Pravastatin 80 mg | Safety of Escalating Doses of Pravastatin as Assessed by Number of Adverse Events | 4 AEs Grade 3 or Higher |